
    
      This is a Phase 1, open-label, multiple-dose study of the safety and tolerability of 2 dose
      levels of REN001 in subjects with fatty acid oxidation disorders (FAODs) with confirmed
      mutations in the Carnitine palmitoyltransferase II deficiency (CPT2), Very long-chain
      Acyl-CoA dehydrogenase deficiency (VLCAD), Long-chain 3-hydroxyacyl-CoA dehydrogenase
      deficiency (LCHAD) or Trifunctional Protein Deficiency (TFP). All subjects will provide
      written consent prior to commencing any study related activities or assessments. Potential
      subjects will be screened for study participation up to 8 weeks prior to the start of
      dosing.The study is divided into two parts, Part A and Part B. Part A has finished enrollment
      and further eligible patients will participate in Part B only.
    
  